Coherus BioSciences (CHRS) Tops Q3 EPS by 15c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.50 +1.35%
Revenue Growth %: +40.6%
Financial Fact:
Other income: 348K
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +40.6%
Financial Fact:
Other income: 348K
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.01), $0.15 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $70.77 million versus the consensus estimate of $58.98 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Assumes Prada SpA (1913:HK) (PRDSY) at Equalweight
- RBC Capital Starts Innio NV (INIO) at Sector Perform
- JPMorgan Starts Graphic Packaging Holding Company (GPK) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
